New drug combo aims to shrink tough pancreatic tumors
NCT ID NCT06844422
First seen Apr 29, 2026 · Last updated May 16, 2026 · Updated 6 times
Summary
This study tests a new drug called ivonescimab, which targets the immune system and tumor blood vessels, combined with targeted radiation and chemotherapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination is safe and can help control the cancer longer. About 37 participants will take part in two phases: first to find the best dose, then to measure how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Cancer Hospital and Institute
RECRUITINGJinan, Shandong, 0531, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.